Sarepta (SPRT) volatility elevated into announcing FDA requesting more data up into FDA review of eteplirsen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 5% to two-week high after Trump says deal with Iran 'over'
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Piper Jaffray Remains Negative on Sarepta (SRPT), 'Unable to Handicap Chances for AA'
June 7, 2016 9:08 AM EDTPiper Jaffray analyst Edward Tenthoff maintained an Underperform rating and $6 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA requested Sarepta provide additional dystrophin data from the ongoing confirmatory PROMOVI trial of eteplirsen. Sarepta plans to submit western blot data from biopsy... More
Sarepta (SRPT): Accelerated Approval Seen Pending Dystrophin Data Analysis - Oppenheimer
June 7, 2016 6:49 AM EDTOppenheimer analyst, Christopher Marai, reiterated his Outperform rating after Sarepta Therapeutic (NASDAQ: SRPT) announced the FDA has requested dystrophin data (n=13) from ongoing PROMOVI confirmatory trial of eteplirsen, prior to making an approval decision. SRPT indicated to us biopsies have been completed but... More
